You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
歌禮製藥(01672.HK)ASC47肥胖症聯合療法完成美國臨床研究受試者給藥
阿思達克 07-15 08:52
歌禮製藥(01672.HK)公布,自主研發的脂肪靶向THR-BETA激動劑ASC47,聯合司美格魯(月太)治療肥胖症的美國臨床研究已完成所有28例受試者給藥,預計於今年第四季可獲頂線數據。 該研究於2025年5月啟動入組,旨在評估超長效皮下注射ASC47單次給藥聯合司美格魯(月太),對不伴有2型糖尿病的肥胖受試者的安全性、耐受性及初步療效。歌禮製藥創始人、董事會主席兼首席執行官吳勁梓表示,試驗正如期穩步推進,快速入組反映業界對減重聯合療法存在濃厚興趣。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account